Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.
A user is developing an AI-powered app for hair loss that includes features like hair loss stage detection and hairline tracking. They seek feedback to ensure the app is useful and emphasize privacy and affordability.
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
CRISPR Cas9 could potentially treat baldness by targeting specific genes in hair follicles without affecting other body functions. There is optimism about its future use, despite ethical concerns and the current reliance on treatments like minoxidil and finasteride.
The post discusses the potential of GT20029 in treating hair loss, questioning if it will replace finasteride or be used alongside existing treatments. A reply indicates that its role is still uncertain.
PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.
Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.
The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.
Chinese researchers have successfully created hair follicles in vitro, potentially offering unlimited hair for transplantation and a cure for hair loss. They plan to test these follicles in vivo on human scalps.
A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
A 57-year-old man uses a hair system, not a hair transplant, and likely had cosmetic procedures. Discussions include the effectiveness of hair systems and finasteride side effects.
Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.
GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.
The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.
Stem cell treatment research shows promise in reversing hair loss in mice, but it's likely 10 years away and expensive. Current recommended treatments include minoxidil, finasteride, and hair transplants.
The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.
The conversation discusses promising hair cloning research seeking commercialization partners. Cultured hairs formed with pigment, indicating positive progress.
Developing new hair loss treatments is challenging due to the complexity and cost of trials, and a permanent cure is unlikely soon. Current treatments like Minoxidil and finasteride are used continuously because hair loss is progressive, and future possibilities include gene editing and hair cloning.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
Gene editing for hair loss is not yet viable due to technological and economic challenges. Current treatments like Minoxidil, finasteride, and hair transplants remain the most practical options.
Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.
A user is organizing a group buy for various compounds aimed at reversing hair loss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.
User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.
CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.
RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
Hair cloning was predicted to be a baldness cure within 3-4 years in 2004, but it has not materialized. Users express frustration and skepticism about the delay.